HeartSciences Q3 net loss narrows 22% to USD 1.99 million

Reuters03-17

HeartSciences Q3 net loss narrows 22% to USD 1.99 million

HeartSciences filed a quarterly report on Form 10-Q for the quarter ended Jan. 31, 2026, reporting a net loss of USD 1.99 million, down 22% year over year. Research and development expense was USD 0.64 million, down 38% due mainly to reduced cloud consulting costs after completing phase 1 of the MyoVista Insights platform and capitalization of software costs. Selling, general and administrative expense was USD 1.29 million. For the nine months ended Jan. 31, 2026, net loss was USD 6.39 million and net cash used in operating activities was USD 5.75 million. The company said existing cash is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern, and noted it submitted the MyoVista wavECG device to the FDA for 510(k) clearance in December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-008399), on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620499935?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620499935","market":"nz","top_or_hot":-1,"title":"HeartSciences Q3 net loss narrows 22% to USD 1.99 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HeartSciences Q3 net loss narrows 22% to USD 1.99 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HeartSciences filed a quarterly report on Form 10-Q for the quarter ended Jan. 31, 2026, reporting a net loss of USD 1.99 million, down 22% year over year. Research and development expense was USD 0.64 million, down 38% due mainly to reduced cloud consulting costs after completing phase 1 of the MyoVista Insights platform and capitalization of software costs. Selling, general and administrative expense was USD 1.29 million. For the nine months ended Jan. 31, 2026, net loss was USD 6.39 million and net cash used in operating activities was USD 5.75 million. The company said existing cash is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern, and noted it submitted the MyoVista wavECG device to the FDA for 510(k) clearance in December 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-008399), on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HeartSciences Q3 net loss narrows 22% to USD 1.99 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeartSciences Q3 net loss narrows 22% to USD 1.99 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 04:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HeartSciences Q3 net loss narrows 22% to USD 1.99 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HeartSciences filed a quarterly report on Form 10-Q for the quarter ended Jan. 31, 2026, reporting a net loss of USD 1.99 million, down 22% year over year. Research and development expense was USD 0.64 million, down 38% due mainly to reduced cloud consulting costs after completing phase 1 of the MyoVista Insights platform and capitalization of software costs. Selling, general and administrative expense was USD 1.29 million. For the nine months ended Jan. 31, 2026, net loss was USD 6.39 million and net cash used in operating activities was USD 5.75 million. The company said existing cash is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern, and noted it submitted the MyoVista wavECG device to the FDA for 510(k) clearance in December 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-008399), on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSCS","symbol_name":"HeartSciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL1PwM4Z:1","article_id":"2620499935","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620499935","pubTimestamp":1773691668,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HeartSciences filed a quarterly report on Form 10-Q for the quarter ended Jan. 31, 2026, reporting a net loss of USD 1.99 million, down 22% year over year. Research and development expense was USD 0.64 million, down 38% due mainly to reduced cloud consulting costs after completing phase 1 of the MyoVista Insights platform and capitalization of software costs. Selling, general and administrative expense was USD 1.29 million. For the nine months ended Jan. 31, 2026, net loss was USD 6.39 million and net cash used in operating activities was USD 5.75 million. The company said existing cash is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern, and noted it submitted the MyoVista wavECG device to the FDA for 510 clearance in December 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HSCS":"HeartSciences Inc","BK4082":"医疗保健设备"},"translate_title":"HeartSciences第三季度净亏损收窄22%至199万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HSCS":0.9},"content_text":"HeartSciences Q3 net loss narrows 22% to USD 1.99 million\n    \n\n        HeartSciences filed a quarterly report on Form 10-Q for the quarter ended Jan. 31, 2026, reporting a net loss of USD 1.99 million, down 22% year over year. Research and development expense was USD 0.64 million, down 38% due mainly to reduced cloud consulting costs after completing phase 1 of the MyoVista Insights platform and capitalization of software costs. Selling, general and administrative expense was USD 1.29 million. For the nine months ended Jan. 31, 2026, net loss was USD 6.39 million and net cash used in operating activities was USD 5.75 million. The company said existing cash is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern, and noted it submitted the MyoVista wavECG device to the FDA for 510(k) clearance in December 2025.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-008399), on March 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620499935","isCrawlerRequest":true}